-
B-lymphocyte depletion with rituximab and β-cell function: two-year results.
Diabetes CarePescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS, Type 1 Diabetes TrialNet Anti-CD20 Study Group. -
A rapid increase in macrophage-derived versican and hyaluronan in infectious lung disease.
Matrix BiolChang MY, Tanino Y, Vidova V, Kinsella MG, Chan CK, Johnson PY, Wight TN, Frevert CW -
Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics.
Scand J ImmunolPieper J, Johansson S, Snir O, Linton L, Rieck M, Buckner JH, Winqvist O, van Vollenhoven R, Malmström V -
CCR7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets.
J Exp MedSmigiel KS, Richards E, Srivastava S, Thomas KR, Dudda JC, Klonowski KD, Campbell DJ -
ADAMTS-4 and biglycan are expressed at high levels and co-localize to podosomes during endothelial cell tubulogenesis in vitro.
J Histochem CytochemObika M, Vernon RB, Gooden MD, Braun KR, Chan CK, Wight TN -
Differential CD4+ T-cell responses of allergic and non-allergic subjects to the immunodominant epitope region of the horse major allergen Equ c 1.
ImmunologyKailaanmäki A, Kinnunen T, Kwok WW, Rytkönen-Nissinen M, Randell J, Virtanen T -
Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.
PLoS OneCerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum CJ, Kita M, Buckner JH, Long SA -
Exonic transcription factor binding directs codon choice and affects protein evolution.
ScienceStergachis AB, Haugen E, Shafer A, Fu W, Vernot B, Reynolds A, Raubitschek A, Ziegler SF, LeProust E, Akey J, Stamatoyannopoulos J -
Basophil depletion downregulates Schistosoma mansoni egg-induced granuloma formation.
Parasitol Int.Anyan WK, Seki T, Kumagai T, Obata-Ninomiya K, Furushima-Shimogawara R, Kwansa-Bentum B, Akao N, Bosompem KM, Boakye DA, Wilson MD, Karasuyama H, Ohta N -
Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.
J AutoimmunDahan R, Gebe JA, Preisinger A, James EA, Tendler M, Nepom GT, Reiter Y -
Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.
DiabetesSosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups. -
Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.
J VirolJames EA, LaFond RE, Gates TJ, Mai DT, Malhotra U, Kwok WW -
Anti-cytokine therapies in T1D: Concepts and strategies.
Clin ImmunolNepom GT, Ehlers M, Mandrup-Poulsen T -
IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Clin ImmunolLong SA, Buckner JH, Greenbaum CJ -
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet Diabetes EndocrinolRigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR, T1DAL Study Team.
